The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer.

[1]  J. Smith-Gagen,et al.  Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy , 2021, Journal of Translational Medicine.

[2]  J. Hodge,et al.  The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy , 2021, Molecular therapy oncolytics.

[3]  A. Mackensen,et al.  Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy , 2021, Cancers.

[4]  M. Hogardt,et al.  Natural Killer Cell Line NK-92-Mediated Damage of Medically Important Fungi , 2021, Journal of fungi.

[5]  M. Gurney,et al.  Generating natural killer cells for adoptive transfer: expanding horizons. , 2021, Cytotherapy.

[6]  W. Wels,et al.  Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting , 2021, Journal for ImmunoTherapy of Cancer.

[7]  Benjamin Wolfson,et al.  Natural Born Killers: NK Cells in Cancer Therapy , 2020, Cancers.

[8]  M. Bouchlaka,et al.  Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. , 2020, Cytotherapy.

[9]  Steven Lin,et al.  Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins , 2020, Frontiers in Immunology.

[10]  S. Benz,et al.  Overcoming hypoxia-induced functional suppression of NK cells , 2020, Journal for ImmunoTherapy of Cancer.

[11]  W. Wels,et al.  CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy , 2019, Front. Immunol..

[12]  R. Eils,et al.  NK cells switch from granzyme B to death receptor–mediated cytotoxicity during serial killing , 2019, The Journal of experimental medicine.

[13]  D. Pierson,et al.  NK cell function is impaired during long-duration spaceflight. , 2019, Journal of applied physiology.

[14]  Y. Diao,et al.  Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy , 2019, International journal of molecular sciences.

[15]  P. Soon-Shiong,et al.  Providing a Homing Receptor for CAR Engineered NK Cells - Improving Cellular Immunotherapy for B-Cell Lymphoma , 2018, Blood.

[16]  D. Kaufman,et al.  Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells , 2018, bioRxiv.

[17]  Chao Yang,et al.  Natural Killer Cells: Development, Maturation, and Clinical Utilization , 2018, Front. Immunol..

[18]  Omkar U. Kawalekar,et al.  CAR T cell immunotherapy for human cancer , 2018, Science.

[19]  T. Whiteside,et al.  Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia , 2017, Scientific Reports.

[20]  Hong Wang,et al.  Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. , 2017, Cytotherapy.

[21]  S. Viswanathan,et al.  A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. , 2017, Oncotarget.

[22]  W. Wels,et al.  Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity , 2017, Front. Immunol..

[23]  P. Soon-Shiong,et al.  Intra-Tumor Injection of CAR-Engineered NK Cells Induces Tumor Regression and Protection Against Tumor Re-Challenge , 2016 .

[24]  J. Schlom,et al.  An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele , 2016, Oncotarget.

[25]  E. Hattingen,et al.  ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. , 2016, Journal of the National Cancer Institute.

[26]  E. Seifried,et al.  CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies , 2016, Journal of cellular and molecular medicine.

[27]  H. Klingemann,et al.  Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells , 2016, Front. Immunol..

[28]  K. Campbell,et al.  NK-92: an “off the shelf” target-specific cytotoxic cell therapeutic , 2015 .

[29]  A. Jauch,et al.  Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  T. Mertens,et al.  Natural Killer Cells Can Inhibit the Transmission of Human Cytomegalovirus in Cell Culture by Using Mechanisms from Innate and Adaptive Immune Responses , 2014, Journal of Virology.

[31]  D. Ojcius,et al.  NK cells kill mycobacteria directly by releasing perforin and granulysin , 2014, Journal of leukocyte biology.

[32]  H. Klingemann.  Are natural killer cells superior CAR drivers? , 2014, Oncoimmunology.

[33]  E. Seifried,et al.  Treatment of patients with advanced cancer with the natural killer cell line NK-92. , 2013, Cytotherapy.

[34]  W. Wels,et al.  Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity , 2013, Oncoimmunology.

[35]  H. Matsubara,et al.  Ex vivo generation of highly purified and activated natural killer cells from human peripheral blood. , 2013, Human gene therapy methods.

[36]  H. Klingemann.  Development and testing of NK cell lines , 2010 .

[37]  H. Klingemann,et al.  Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. , 2008, Cytotherapy.

[38]  P. Bierling,et al.  Dissection of the Role of PfEMP1 and ICAM-1 in the Sensing of Plasmodium falciparum-Infected Erythrocytes by Natural Killer Cells , 2007, PloS one.

[39]  H. Klingemann,et al.  Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia , 2003, Bone Marrow Transplantation.

[40]  Sven Becker,et al.  Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. , 2002, Blood.

[41]  Ying K. Tam,et al.  Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. , 2001, Journal of hematotherapy & stem cell research.

[42]  K. Huppi,et al.  Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. , 1999, Blood.

[43]  V. Ho,et al.  Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92. , 1999, Journal of hematotherapy.

[44]  T. Tonn,et al.  Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. , 1999, Human gene therapy.

[45]  P. Steinherz,et al.  Antileukemia activity of a natural killer cell line against human leukemias. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  H. Klingemann,et al.  A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. , 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  J. Gong,et al.  Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. , 1994, Leukemia.

[48]  S. Steinberg,et al.  Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. , 1993, Journal of the National Cancer Institute.